#United States #healthcare #financial results #Amgen #Thousand Oaks

Amgen's Financial Performance in Q1 2026

Amgen, a leader in biotechnology, has announced its financial results for the first quarter of 2026, revealing strong growth metrics and a resilient operational performance despite anticipated patent expirations and intensifying competition. The company's total revenues rose by 6% year-over-year to reach $8.6 billion, solidifying its strong market position.

Key Highlights

Amgen's impressive performance is attributed to a notable increase in product sales, which grew by 4%. This growth was significantly driven by a 9% increase in volume, although it was slightly tempered by a 2% decline in net selling price and inventory adjustments. Notably, 16 of Amgen's products experienced double-digit growth during this period, and the company boasts 17 products that are projected to generate over $1 billion annually based on initial quarterly sales figures.

Robert A. Bradway, the company’s Chairman and CEO, highlighted the optimism surrounding Amgen's future, stating: "Our first quarter results demonstrate the strength of our business structure, enabling us to navigate through heightened competition effectively. We are on the cusp of introducing several novel molecules that are currently in Phase 3 clinical development."

Financial Metrics

In terms of earnings, Amgen reported a 4% increase in GAAP earnings per share (EPS), rising from $3.20 to $3.34. This upland in EPS was bolstered by an increase in operating income, which surged from $1.2 billion to $2.7 billion, leading to a substantial rise in the GAAP operating margin to 32.4% from 15.0% year-over-year.

Similarly, the non-GAAP EPS also saw a solid increase of 5% landing at $5.15 compared to $4.90 a year ago, confirming sound revenue growth amidst rising operating costs. Amgen generated $1.5 billion in free cash flow in the first quarter—up from $1.0 billion the previous year—indicative of solid cash generation capabilities.

Product Sales Dynamics

Examining Amgen's product sales further, Repatha® (evolocumab) sales led the charge with a remarkable 34% year-over-year increase, achieving $876 million. This spike is primarily a result of volume growth combined with favorable changes to sales deductions, although a reduced selling price slightly offset gains. Meanwhile, EVENITY® (romosozumab-aqqg) grew by 27% year-over-year, demonstrating strong market demand in its respective category.

Contrastingly, some established drugs like Prolia® (denosumab) witnessed a decline of 34%, largely attributed to a combination of lower volume sales, price reductions, and competitive market pressures. Analysts predict a continuing trend of erosion as newer biosimilars enter the market.

Future Outlook

Looking ahead, Amgen maintains a cautiously optimistic stance, projecting total revenues in the range of $37.1 billion to $38.5 billion for the full year 2026. The company plans to continue investing in its pipeline, with expectations of introducing several new products and improving existing ones. With ongoing Phase 3 studies and committed investments in innovation, Amgen is well-prepared to enhance its market position and counter evolving challenges.

In conclusion, Amgen's first-quarter results underline a solid financial foundation equipped with strategic growth measures. These results encapsulate the company's ability to thrive in a competitive landscape while delivering significant product advancements and shareholder value. Stakeholders will be closely monitoring Amgen's developments, especially as new products enter clinical trials and the market.